Small high-density lipoprotein (HDL) subclasses are increased with decreased activity of HDL-associated phospholipase A2 in subjects with prediabetes

Lipids

Volumn 48, Issue 6, 2013, Pages 547-555

  Filippatos, Theodosios D ^a   Rizos, Evangelos C ^a   Tsimihodimos, Vasilios ^a   Gazi, Irene F ^a   Tselepis, Alexandros D ^b   Elisaf, Moses S ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

^b UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Apolipoprotein C II; Apolipoprotein C III; HDL subclasses; Impaired fasting glucose; LDL subclasses; Lipoprotein associated phospholipase A2; Paraoxonase; Prediabetes

Indexed keywords

APOLIPOPROTEIN A; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; APOLIPOPROTEIN C2; APOLIPOPROTEIN C3; APOLIPOPROTEIN E; ARYLDIALKYLPHOSPHATASE; GLUCOSE; HIGH DENSITY LIPOPROTEIN 3; HIGH DENSITY LIPOPROTEIN ASSOCIATED PHOSPHOLIPASE A2; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHOLIPASE A2; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY MASS; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; ENZYME ACTIVITY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; IMPAIRED GLUCOSE TOLERANCE; MAJOR CLINICAL STUDY; MALE; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ADULT; APOLIPOPROTEIN C-II; APOLIPOPROTEIN C-III; ARYLDIALKYLPHOSPHATASE; BLOOD GLUCOSE; FASTING; FEMALE; GREECE; HUMANS; LIPOPROTEINS, HDL; MALE; MIDDLE AGED; PREDIABETIC STATE; RISK FACTORS; TRIGLYCERIDES; WAIST CIRCUMFERENCE;

EID: 84878618571     PISSN: 00244201     EISSN: 15589307     Source Type: Journal    
DOI: 10.1007/s11745-013-3787-1     Document Type: Article

References (51)

1. American Diabetes Association (2008) Economic costs of diabetes in the U.S. in 2007. Diabetes care 31:596-615
2. American Diabetes Association (2012) Standards of medical care in diabetes. Diabetes care 35(Suppl 1):S11-S63
3. Moutzouri E, Tsimihodimos V, Rizos E, Elisaf M (2011) Prediabetes: to treat or not to treat? Eur J Pharmacol 672:9-19
4. Kontush A, Chapman MJ (2006) Antiatherogenic small, dense HDL-guardian angel of the arterial wall? Nat Clin Pract Cardiovasc Med 3:144-153
5. Mueller O, Chang E, Deng D, Franz T, Jing D, Kincaid R, Konigshofer Y, Kratzmeier M, McNulty M, Qian H, Schneider J, Schulte H, Seedorf U, Tian X, Van Cleve M, Yang D, Assmann G (2008) PROCAM Study: risk prediction for myocardial infarction using microfluidic high-density lipoprotein (HDL) sub fractionation is independent of HDL cholesterol. Clin Chem Lab Med 46:490-498
6. Filippatos T, Derdemezis C, Voulgari P, Tsimihodimos V, Elisaf M, Tselepis A, Drosos A (2013). Effects of 12 months of treatment with disease-modifying anti-rheumatic drugs on low and high density lipoprotein subclass distribution in patients with early rheumatoid arthritis: a pilot study. Scand J Rheumatol (epub ahead of print)
7. Kostapanos MS, Milionis HJ, Filippatos TD, Christogiannis LG, Bairaktari ET, Tselepis AD, Elisaf MS (2009) Dose-dependent effect of rosuvastatin treatment on HDL-subfraction phenotype in patients with primary hyperlipidemia. J Cardiovasc Pharmacol Ther 14:5-13
8. Tselepis AD, Chapman JM (2002) Inflammation, bioactive lipids and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor-acetylhydrolase. Atheroscler 3:57-68
9. James RW (2006) A long and winding road: defining the biological role and clinical importance of paraoxonases. Clin Chem Lab Med 44:1052-1059
10. Farbstein D, Levy AP (2012) HDL dysfunction in diabetes: causes and possible treatments. Expert Rev Cardiovasc Ther 10:353-361
11. Filippatos TD, Kiortsis DN, Liberopoulos EN, Georgoula M, Mikhailidis DP, Elisaf MS (2005) Effect of orlistat, micronised fenofibrate and their combination on metabolic parameters in overweight and obese patients with the metabolic syndrome: the FenOrli study. Curr Med Res Opin 21:1997-2006
12. Sakurabayashi I, Saito Y, Kita T, Matsuzawa Y, Goto Y (2001) Reference intervals for serum apolipoproteins A-I, A-II, B, C-II, C-III, and E in healthy Japanese determined with a commercial immunoturbidimetric assay and effects of sex, age, smoking, drinking, and Lp(a) level. Clin Chim Acta 312:87-95
13. Filippatos T, Tsimihodimos V, Kostapanos M, Kostara C, Bairaktari E, Kiortsis D, Elisaf M (2008) Analysis of the 6-month effect of orlistat, alone or in combination with fenofibrate, administration on triglyceride-rich lipoprotein metabolism in overweight and obese patients with metabolic syndrome. J Clin Lipidol 2:279-284
14. Nakou ES, Filippatos TD, Agouridis AP, Kostara C, Bairaktari ET, Elisaf MS (2010) The effects of ezetimibe and/or orlistat on triglyceride-rich lipoprotein metabolism in obese hypercholesterolemic patients. Lipids 45:445-450
15. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ (2004) Implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines. J Am Coll Cardiol 44:720-732
16. Filippatos TD, Liberopoulos EN, Kostapanos M, Gazi IF, Papavasiliou EC, Kiortsis DN, Tselepis AD, Elisaf MS (2008) The effects of orlistat and fenofibrate, alone or in combination, on high-density lipoprotein subfractions and pre-beta1-HDL levels in obese patients with metabolic syndrome. Diabetes Obes Metab 10:476-483
17. Tselepis AD, Dentan C, Karabina SA, Chapman MJ, Ninio E (1995) PAF-degrading acetylhydrolase is preferentially associated with dense LDL and VHDL-1 in human plasma. Catalytic characteristics and relation to the monocyte-derived enzyme. Arterioscler Thromb Vasc Biol 15:1764-1773
18. Nakou ES, Filippatos TD, Georgoula M, Kiortsis DN, Tselepis AD, Mikhailidis DP, Elisaf MS (2008) The effect of orlistat and ezetimibe, alone or in combination, on serum LDL and small dense LDL cholesterol levels in overweight and obese patients with hypercholesterolaemia. Curr Med Res Opin 24:1919-1929
19. Tzotzas T, Filippatos TD, Triantos A, Bruckert E, Tselepis AD, Kiortsis DN (2008) Effects of a low-calorie diet associated with weight loss on lipoprotein-associated phospholipase A2 (Lp-PLA2) activity in healthy obese women. Nutr Metab Cardiovasc Dis 18:477-482
20. Tsimihodimos V, Karabina SA, Tambaki AP, Bairaktari E, Goudevenos JA, Chapman MJ, Elisaf M, Tselepis AD (2002) Atorvastatin preferentially reduces LDL-associated platelet-activating factor acetylhydrolase activity in dyslipidemias of type IIA and type IIB. Arterioscler Thromb Vasc Biol 22:306-311
21. Nakou ES, Filippatos TD, Kiortsis DN, Derdemezis CS, Tselepis AD, Mikhailidis DP, Elisaf MS (2008) The effects of ezetimibe and orlistat, alone or in combination, on high-density lipoprotein (HDL) subclasses and HDL-associated enzyme activities in overweight and obese patients with hyperlipidaemia. Expert Opin Pharmacother 9:3151-3158
22. Filippatos TD, Gazi IF, Liberopoulos EN, Athyros VG, Elisaf MS, Tselepis AD, Kiortsis DN (2007) The effect of orlistat and fenofibrate, alone or in combination, on small dense LDL and lipoprotein-associated phospholipase A2 in obese patients with metabolic syndrome. Atherosclerosis 193:428-437
23. Rashid S, Uffelman KD, Lewis GF (2002) The mechanism of HDL lowering in hypertriglyceridemic, insulin-resistant states. J Diabetes Complicat 16:24-28
24. Coniglio RI, Merono T, Montiel H, Malaspina MM, Salgueiro AM, Otero JC, Ferraris R, Schreier L, Brites F, Gomez Rosso L (2012) HOMA-IR and non-HDL-C as predictors of high cholesteryl ester transfer protein activity in patients at risk for type 2 diabetes. Clin Biochem 45:566-570
25. Julius U, Jauhiainen M, Ehnholm C, Pietzsch J (2007) Lipid transfer protein activities in subjects with impaired glucose tolerance. Clin Chem Lab Med 45:237-243
26. Rashid S, Watanabe T, Sakaue T, Lewis GF (2003) Mechanisms of HDL lowering in insulin resistant, hypertriglyceridemic states: the combined effect of HDL triglyceride enrichment and elevated hepatic lipase activity. Clin Biochem 36:421-429
27. von Eckardstein A, Nofer JR, Assmann G (2001) High density lipoproteins and arteriosclerosis. Role of cholesterol efflux and reverse cholesterol transport. Arterioscler Thromb Vasc Biol 21:13-27
28. Lagos KG, Filippatos TD, Tsimihodimos V, Gazi IF, Rizos C, Tselepis AD, Mikhailidis DP, Elisaf MS (2009) Alterations in the high density lipoprotein phenotype and HDL-associated enzymes in subjects with metabolic syndrome. Lipids 44:9-16
29. Wang J, Stancakova A, Soininen P, Kangas AJ, Paananen J, Kuusisto J, Ala-Korpela M, Laakso M (2012) Lipoprotein subclass profiles in individuals with varying degrees of glucose tolerance: a population-based study of 9399 Finnish men. J Intern Med 272:562-572
30. Tian L, Long S, Li C, Liu Y, Chen Y, Zeng Z, Fu M (2012) High-density lipoprotein subclass and particle size in coronary heart disease patients with or without diabetes. Lipids Health Dis 11:54
31. Festa A, Williams K, Hanley AJ, Otvos JD, Goff DC, Wagenknecht LE, Haffner SM (2005) Nuclear magnetic resonance lipoprotein abnormalities in prediabetic subjects in the insulin resistance atherosclerosis study. Circulation 111:3465-3472
32. Morgan J, Carey C, Lincoff A, Capuzzi D (2004) High-density lipoprotein subfractions and risk of coronary artery disease. Curr Atheroscler Rep 6:359-365
33. Asztalos BF, Cupples LA, Demissie S, Horvath KV, Cox CE, Batista MC, Schaefer EJ (2004) High-density lipoprotein subpopulation profile and coronary heart disease prevalence in male participants of the Framingham Offspring Study. Arterioscler Thromb Vasc Biol 24:2181-2187
34. Asztalos BF, Collins D, Cupples LA, Demissie S, Horvath KV, Bloomfield HE, Robins SJ, Schaefer EJ (2005) Value of high-density lipoprotein (HDL) subpopulations in predicting recurrent cardiovascular events in the Veterans affairs HDL intervention trial. Arterioscler Thromb Vasc Biol 25:2185-2191
35. Sakuma N, Yoshikawa M, Hibino T, Ohte N, Kamiya T, Kunimatsu M, Kimura G, Inoue M (2002) HDL3 exerts a more powerful antiperoxidative and protective effect against peroxidative modification of LDL than HDL2 does. J Nutr Sci Vitaminol (Tokyo) 48:278-282
36. Francis GA (2010) The complexity of HDL. Biochim Biophys Acta 1801:1286-1293
37. Nobecourt E, Jacqueminet S, Hansel B, Chantepie S, Grimaldi A, Chapman MJ, Kontush A (2005) Defective antioxidative activity of small dense HDL3 particles in type 2 diabetes: relationship to elevated oxidative stress and hyperglycaemia. Diabetologia 48:529-538
38. Morgantini C, Natali A, Boldrini B, Imaizumi S, Navab M, Fogelman AM, Ferrannini E, Reddy ST (2011) Anti-inflammatory and antioxidant properties of HDLs are impaired in type 2 diabetes. Diabetes 60:2617-2623
39. Ragbir S, Farmer JA (2010) Dysfunctional high-density lipoprotein and atherosclerosis. Curr Atheroscler Rep 12:343-348
40. Otocka-Kmiecik A, Mikhailidis DP, Nicholls SJ, Davidson M, Rysz J, Banach M (2012) Dysfunctional HDL: a novel important diagnostic and therapeutic target in cardiovascular disease? Prog Lipid Res 51:314-324
41. Tellis CC, Tselepis AD (2009) The role of lipoprotein-associated phospholipase A2 in atherosclerosis may depend on its lipoprotein carrier in plasma. Biochim Biophys Acta 1791:327-338
42. Gazi I, Lourida ES, Filippatos T, Tsimihodimos V, Elisaf M, Tselepis AD (2005) Lipoprotein-associated phospholipase A2 activity is a marker of small, dense LDL particles in human plasma. Clin Chem 51:2264-2273
43. Besler C, Heinrich K, Riwanto M, Luscher TF, Landmesser U (2010) High-density lipoprotein-mediated anti-atherosclerotic and endothelial- protective effects: a potential novel therapeutic target in cardiovascular disease. Curr Pharm Des 16:1480-1493
44. Mackness MI, Mackness B, Durrington PN, Connelly PW, Hegele RA (1996) Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins. Curr Opin Lipidol 7:69-76
45. Mackness MI, Mackness B, Durrington PN (2002) Paraoxonase and coronary heart disease. Atheroscler 3:49-55
46. Gazi IF, Tsimihodimos V, Tselepis AD, Elisaf M, Mikhailidis DP (2007) Clinical importance and therapeutic modulation of small dense low-density lipoprotein particles. Expert Opin Biol Ther 7:53-72
47. Gazi I, Tsimihodimos V, Filippatos T, Bairaktari E, Tselepis AD, Elisaf M (2006) Concentration and relative distribution of low-density lipoprotein subfractions in patients with metabolic syndrome defined according to the national cholesterol education program criteria. Metabolism 55:885-891
48. Dell'Omo G, Penno G, Del Prato S, Mariani M, Pedrinelli R (2009) Dysglycaemia in non-diabetic hypertensive patients: comparison of the impact of two different classifications of impaired fasting glucose on the cardiovascular risk profile. J Hum Hypertens 23:332-338
49. Ooi EM, Barrett PH, Chan DC, Watts GF (2008) Apolipoprotein C-III: understanding an emerging cardiovascular risk factor. Clin Sci (Lond) 114:611-624
50. Kei AA, Filippatos TD, Tsimihodimos V, Elisaf MS (2012) A review of the role of apolipoprotein C-II in lipoprotein metabolism and cardiovascular disease. Metabolism 61:906-921
51. Filippatos TD, Tsimihodimos V, Kostapanos M, Kostara C, Bairaktari E, Kiortsis DN, Tselepis AD, Elisaf M (2008) Small dense LDL cholesterol and apolipoproteins C-II and C-III in non-diabetic obese subjects with metabolic syndrome. Arch Med Sci 4:263-269